Intercept Pharmaceuticals Inc ICPT
Morningstar Growth Grade = A
Projected Annual Return = 17%
June 24, 2021 price = $21.19
Company Profile
Business Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Contact10 Hudson Yards, 37th Floor
New York, NY, 10001
New York, NY, 10001
T +1 646 747-1000
SectorHealthcare
IndustryBiotechnology
Most Recent EarningsMar 31, 2021
Fiscal Year EndDec 31, 2021
No comments:
Post a Comment